Risk Factors for CRS and ICANS with Tarlatamab in Small Cell Lung Cancer and Associated Efficacy Outcomes: Insights from Clinical Practice

High disease burden, hepatic disease, and baseline oxygen use may increase CRS risk with high disease burden and CNS disease driving ICANS risk. Tarlatamab demonstrated manageable toxicity with clinically relevant efficacy across high-risk patient populations supporting broad access to this therapy.